HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M500387-MCP200v1 5/6/1095    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ru, Q. C. Articles by Shriver, C. D. Search for Related Content PubMed PubMed Citation Articles by Ru, Q. C. Articles by Shriver, C. D. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:1095-1104, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Label-free Semiquantitative Peptide Feature Profiling of Human Breast Cancer and Breast Disease Sera via Two-dimensional Liquid Chromatography-Mass Spectrometry^*,S

Qinhua Cindy Ru^,, Luwang Andy Zhu, Jordan Silberman and Craig D. Shriver^¶

From the Windber Research Institute, Windber, Pennsylvania 15963 and ^¶ Clinical Breast Care Project Administration Office, Walter Reed Army Medical Center, Washington, D. C. 20307

A label-free semiquantitative peptide feature profiling method was developed in response to challenges associated with analysis of two-dimensional liquid chromatography-tandem mass spectrometry data. One hundred twenty human sera (49 from invasive breast carcinoma patients, 26 from non-invasive breast carcinoma patients, 35 from benign breast disease patients, and 10 from normal controls) were repeatedly analyzed using a standardized two-dimensional liquid chromatography-mass spectrometry method. Data were extracted using the novel semiquantitative peptide feature profiling method, which is based on comparisons of normalized relative ion intensities. Hierarchical cluster analyses and principle component analyses were used to evaluate the predicative capability of the extracted data, and results were promising. Extracted data were also randomly assigned to either a training group (65%) or to a test group (35%) for artificial neural network modeling. Models best identified invasive breast carcinomas (212 predictions, 94% accurate) and benign non-neoplastic breast disease (96 predictions, 81.3% accurate). These results suggest that, after further development, the novel method may be useful for large scale clinical proteomic profiling.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Ocak, P. Chaurand, and P. P. Massion Mass Spectrometry-based Proteomic Profiling of Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 159 - 170. [Abstract] [Full Text] [PDF]

				Y. Kinoshita, T. Uo, S. Jayadev, G. A. Garden, T. P. Conrads, T. D. Veenstra, and R. S. Morrison Potential Applications and Limitations of Proteomics in the Study of Neurological Disease Arch Neurol, December 1, 2006; 63(12): 1692 - 1696. [Full Text] [PDF]